Dengue guideline 082012, grade dhf, dengue, indonesia


Published on

from dr. Ida Savitri, SpA(K)

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Dengue guideline 082012, grade dhf, dengue, indonesia

  1. 1. Case 1 Anak perempuan 7 th dirujuk oleh SpA ke RSS dengan: Demam naik turun 4 hari Mual (+), muntah (-), hepatomegali , RL (+) Pada hari dirujuk diperiksa lab dengan hasil : Hct : 39%, Hb:12,4, JL: 4000/uL, diftel DBN, JT: 150.000/uL. NS1 Dengue (-)Q: Apa diagnosis kerja/ DD pasien ini?
  2. 2. Case 2 Anak laki2, 4 th datang ke poli/ IRD RSS dengan : Demam tinggi naik turun , 2 hari Batuk sedikit, tidak pilek Mual/muntah (-) Pusing Menurut ibu ada anak tetangga yang dirawat di RSS 1 minggu yll dengan DBQ: Apa diagnosis kerja/DD anak ini?
  3. 3. Ida Safitri LaksonoDept of Child Health, Faculty of Medicine UGM RSUP Dr. Sardjito, Yogyakarta
  4. 4. Outline of presentation Introduction Overview of the three guidelines Dengue Guideline 1997 Background and evidence related to Dengue Guideline 2009 Dengue Guideline 2011 National Dengue Guideline? Summary
  5. 5. IntroductionGLOBAL burden of dengue Global incidence of dengue has grown dramatically in recent decades About two fifths of the worlds population are now at risk Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas Dengue is the most prevalent arboviral disease with high morbidity, mortality & socio-economical costs.
  6. 6. Cont…Case management Despite its complexity in pathogenesis and manifestation  the management is relatively simple and inexpensive No specific treatment  rely on fluid management. Appropriately and timely implemented, it could save the lives of patients Current situation : the most effective way to prevent dengue transmission is to combat disease-carrying mosquitoes The development of vaccines and drugs is challenging but potential to change this.
  7. 7. 1997 2009 2011
  8. 8. Dengue guidelines 1997 2009 2011 Guideline for treatment Dengue – Guidelines for Comprehensive guidelineTitle of DF and DHF in small diagnosis, treatment, for prevention and hospitals – WHO Searo prevention and control – control of Dengue and 1999 WHO TDR 2009 DHF – WHO Searo 2011Pages 33 160 212 Clinical manifestation, Chapters : (6) Chapters : (15) diagnosis, case management Epidemiology and burden of Epidemiology, disease disease, clinical burden,clinical management, vector manifestation and diagnosis,Content management, lab diagnostic lab diagnosis, management, tests, surveillance and surveillance, vector, vector emergency response, new management, IVM, Combi, avenues PHC approach, case investigation, monitoring, strategic plan (bi-regional plan)
  9. 9. Diagnosis Classification 1997 2009 2011Dengue fever Dengue without Dengue fever warning signsDHF grade I Dengue with warning DHF grade I signsDHF grade II DHF grade IIDHF grade III Severe dengue DHF grade III ( severe plasma leakage, severe hemorrhage, severe organ involvement)DHF grade IV DHF grade IV * Expanded dengue syndrome Adult management Adult management
  10. 10.  Probable – an acute febrile illness with two or more of the following manifestations:  Headache  Retro-orbital pain  Myalgia  Arthralgia  Rash  Haemorrhagic manifestations  Leukopenia; and  Supportive serology (a reciprocal HI antibody titre ≥1280, a comparable IgG ELISA titre or a positive IgM antibody test on a late acute or convalescent-phase serum specimen ); or  Occurence at the same location and time as other confirmed cases of dengue fever. Confirmed – a case confirmed by laboratory criteria Reportable – any probable or confirmed case should be reported
  11. 11. Grade Sign and Symptomps LaboratoryDF DHF without plasma leakageDHF I Fever with non-specific constitutional Thrombocytopenia symptoms; the only hemorrhagic (platelet count manifestation is a positive tourniquet test 100,000/ L) &/or easy bruising evidence of plasma leakage II DHF grade I plus spontaneous bleeding III Circulatory failure manifested by a rapid, weak pulse, narrowing of pulse pressure, or hypotension, cold & clammy skin, restlessness IV Profound shock with undetectable blood pressure
  12. 12. WHO Dengue Classification 1997 DF DHF1. Fever 2-7 days + +2. Bleeding tendency   Positive tourniquet test or Spontaneous bleeding +/- +3. Thrombocytopaenia  ≤ 100,000/mm³ +/- +4. Plasma leakage Pleural effusion /ascites - +  /hypoproteinaemia  ≥ 20% increase in HCT from baseline
  13. 13. Lancet Inf Dis 2006; 6: 297-302 Lancet 2006; 368: 170-173
  14. 14. The stages of the dengue case classification development1 Numerous publications describing the - numerous reports of the difficulties using9 difficulties using DF/DHF/DSS DF/DHF/DSS: epidemiology has changed9 A systematic review of the issue - confirmation of the above0 Bandyopadhyay S et al., TMIH 2006, Volume 11 no 8 pp 1238–1255´s The DenCo study - clear evidence for classifying in dengue - (dengue and control) and severe dengue2 DF/DHF/DSS application study - large differences of DHF case definitions0 Santamaria R et al. , accepted at TMIH 2009, September between countries; application difficult - dengue is just one disease entity with0 Two expert consensus meetings different clinical presentations and often with La Habana 2007 and Kuala Lumpur 20079 unpredictable clinical evolution and outcome A global expert consensus meeting -further design: 1) dengue with or without Geneva 2008 warning signs and 2) severe dengue Dengue guidelines validation studies - analysis showing user-friendliness (forthcoming publication) and acceptance of dengue/severe dengue A global expert meeting reviewing - final analysis and recommendations "chain of evidence“ (planned for 03/2010) TDR report (summary recommendations) - overall summary report/recommendations (planned for 03/2010)
  15. 15. The full model of the revised WHO dengue case classification Dengue case classification by severity Dengue ± warning signs Severe dengue with 1.Severe plasma leakage Without warning signs 2.Severe haemorrhage 3.Severe organ impairment Criteria for dengue ± warning signs Criteria for severe dengueProbable dengue Warning signs* 1. Severe plasma leakageLive in/travel to dengue • Abdominal pain or leading to:endemic area. Fever and 2 tenderness • Shock (DSS)of the following criteria: • Persistent vomiting • Fluid accumulation with• Nausea, vomiting • Clinical fluid accumulation respiratory distress• Rash • Mucosal bleed• Aches and pains • Lethargy; restlessness 2. Severe bleeding• Tourniquet test positive • Liver enlargement >2cm as evaluated by clinician• Leucopenia • Laboratory: Increase in HCT 3. Severe organ involvement• Any warning sign concurrent with rapid • Liver: AST or ALT>=1000Laboratory confirmed decrease in platelet count WHO/TDR 2009 • CNS: Impaireddengue(important when no sign of plasma * Requiring strict observation consciousnessleakage) and medical intervention • Heart and other organs
  16. 16. Dengue without warning signsProbable denguelive in /travel to dengue endemic area.Fever and 2 of the following criteria:• Nausea, vomiting• Rash• Aches and pains• Tourniquet test positive• Leucopenia• (Any warning sign)
  17. 17. Dengue with warning signsWarning signs ( appear in the critical period)* Abdominal pain or tenderness Persistent vomiting Clinical fluid accumulation Mucosal bleed Lethargy, restlessness Liver enlargement >2 cm Increase in HCT concurrent with rapid decrease in platelet count back
  18. 18. Severe Dengue Severe plasma leakage leading to: • Shock (DSS) • Fluid accumulation with respiratory distress Severe bleeding as evaluated by clinician Severe organ involvement  Liver: AST or ALT ≥ 1000  CNS: Impaired consciousness  Heart and other organs
  19. 19. Evidence from 2009 Dengue Guideline Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries (Neal Alexander, 2011) Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity  Sensitivity and specificity to capture Category III care for DHF/DSS were 39.0% and 75.5%, respectively; sensitivity and specificity for SD were 92.1% and 78.5%, respectively (Federico Narvaez, 2011)
  20. 20. Evidence from 2009 Dengue Guideline Usefulness and applicability of the revised dengue case classification by disease: multicentre study in 18 countries (Judit Barniol, 2010) Dengue—How Best to Classify It (Anon Srikiatkhachorn, 2011)• Application of revised dengue classification criteria as a severity marker of dengue viral infection in Indonesia  Binary logistic regression showed the revised dengue classification system (p = 0.000, Wald:22.446) was better in detecting severe dengue infections than the WHO classification system (p = 0.175, Wald:6.339) (Basuki PS, 2010)
  21. 21. Dengue virus infection 2011 Asymptomatic Symptomatic Expanded Dengue syndrome/isolatedUndefferentiated organophaty (unusual fever manifestation)(viral syndrome) Dengue Haemorrhagic Dengue Fever Fever (DHF) (DF) (with plasma leakage) Without With unusual DHF non DHF with shock haemorrhage haemorrhage shock Dengue Shock Syndrome (DSS)
  22. 22. WHO classification of Dengue infections and grading of severity of DHF (2011)DF/DHF Grade Signs and Symptoms LaboratoryDF Fever with two of the following: • Leucopenia (WBC <5000 cells/mm3) • Headache • Thrombocytopenia <150.000 • Retro-orbital pain cells/mm3) • Myalgia • Rising Hct (5-10%) • Athralgia/bone pain • No evidence of plasma loss • Rash • Haemorrhagic manifestations • No evidence of plasma leakageDHF I Fever and haemorrhagic manifestation Thrombocytopenia <100.000 cells/mm3 (positive tourniquet test) and evidence Hct rise >20% of plasma leakageDHF II As in Grade I plus spontaneous bleeding Thrombocytopenia <100.000 cells/mm3 Hct rise >20%*DHF III As in Grade I or II plus circulatory Thrombocytopenia <100.000 cells/mm3 failure Hct rise >20%*DHF IV As in Grade III plus profound shock with Thrombocytopenia <100.000 cells/mm3 undetectable bloodpressure and pulse Hct rise >20%*DHF III and IV are DSS
  23. 23. clinical and laboratory finding from patients Hospitalized in pediatric ward RS Dr. Sardjito – 2006 DF (%) DHF (%) OR (95%CI) 24 48Cough-coryza 5 (20) 8 (16) 0.76 (0.22-2.63),p=0.91Headache 12 (50) 29 (60) 1.52 (0.57-4.00), p=0.55Abdominal pain 7 (29) 25 (52) 2.64 (0.92-7.5), p=0.11Nausea-vomiting 10 (41) 18 (37) 0.84 (0.30-2.30), p=0.93Arthralgia 18 (75) 37 (77) 1.12 (0.35-3.5), p=0.92Hepatomegaly 12 (50) 40 (83) 5 (1.66-15.00),p<0.01Bleeding 5 (20) 17 (35) 1.28 (0.48-3.5), p=0.80-epistaxis 6 (25) 15 (31)-petekie 0 (0) 14 (29)-gastrointestinal 0 2 (1)-hematuriaLeucopenia 15 (62) 40 (83) 3 (0.97-9.21), p=0.09(AL<4000)Platelet <100.000 12 (50) 41 (85) 5.85 (1.88-18.17), p=<0.01 Confirmed by serology26
  24. 24. Admission criteria 1997 2009 2011Admission CriteriaSigns of significant - Any warning sign - Shock: Resuscitationdehydration (>10% - Coexisting conditions: and admission.normal body weight) infancy, pregnancy, old -Hypoglycemic patients age, obesity, diabetes without leucopenia mellitus, renal failure, and/or thrombocytopenia hypertension, chronic -Those with warning hemolytic disease etc. signs. - Social circumstances: - High-risk patients with living alone, living far leucopenia and from health facility, thrombocytopenia without reliable means of transport. Home care card 1997 2009 2011 No Yes Yes
  25. 25. Warning signs 2009 & 2011 2009 2011 Abdominal pain + severe + or tenderness Persistent vomiting, + + , lack of water intake Clinical fluid accumulaton + - Bleeding Mucosal Epistaxis, black stool, haematemesis, excessive bleed menstrual bleeding, dark-coloured urine (haemoglobinuria) or haematuria. Lethargy and/or restlessness + + , sudden behavioural changes Liver enlargement > 2 cm + -Increase in Hct concurrent with rapid + - decrease in platelet count No clinical improvement or - + worsening of the situation Giddiness - + Pale,cold, a clammy hands and feet - + Less/no urine output for 4–6 hours - +
  26. 26. WHO Searo 2011,
  27. 27.  The first two clinical criteria, plus thrombocytopenia and hemoconcentration or a rising Hct are sufficient to establish a “clinical diagnosis of DHF”. The presence of liver enlargement in adition to the first two clinical criteria is suggesting of DHF before the onzet of plasma leakage. ( WHO Searo 2011, p.24)
  28. 28. Fluid management 1997 2009 2011DHF grade I-II Dengue with warning DHF grade I-II signs6-7 ml/kg/hour 5 isotonic solutions such as maintenance (for oneml/kg/hour 3 0.9% saline, Ringer’s day) + 5% deficit (oralml/kg/hour – stop after lactate, or Hartmann’s and IV fluid together), to24-48 hours solution. Start with 5–7 be administered over 48 ml/kg/hour for 1–2 hours, hours then reduce to 3–5 ml/kg/hr for 2–4 hours, and then reduce to 2–3 ml/kg/hr or less according to the clinical response
  29. 29. Cont… 1997 2009 2011DSS Severe Dengue- DHF grade III compensated shock10-20 ml/kgBB bolus, isotonic crystalloid 10 ml/kg in children orrepeat if necessary solutionsat 5–10 300–500 ml in adults over algorithm ml/kg/hour over one one hour or by bolus, if hour. →reassess necessary Further, fluid administration should follow the graph
  30. 30. Cont… 2009 2011Severe Dengue – hypotensive shock DHF grade IVStart with crystalloid or colloid 10 ml/kg of bolus fluid (10-15 min)solution (if available) at 20 ml/kg asa bolus given over 15 minutes to When the blood pressure is restored,bring the patient out of shock as further intravenous fluid may be givenquickly as possible. as in Grade 3. If shock is not reversible after the first 10 ml/kg, a repeat bolus of 10 ml/kg and laboratory results should be pursued and corrected as soon as possible.
  31. 31. Transfusion in Severe Bleeding 2009 2011Give 5–10ml/kg of fresh-PRC or 10– 10 ml/kg of FWB or 5 ml/kg of freshly20ml/kg of FWB at an appropriate rate PRCand observe the clinical response. Reassess, repeat if necessary
  32. 32. Discharge criteria Criteria 1997 2009 2011 Absence of fever 24 hours 48 hours 24 hours without the without the use of anti- use of anti- fever therapy fever therapy Clinical + + (general well-being, appetite, + improvement hemodynamic status, urine output, no respiratory distress)Return of appetite + - +Good urine output + - +Stable hematocrit + + (without intravenous fluids) +Elapse from shock At least 2 days - At least 2-3 recovery days No respiratory + - + distress Platelet count > 50,000/ L Increasing trend > 50,000/ L
  33. 33. National guideline Ditjen PPM –PLP 2004 Ditjen Yanmed , IDAI, PAPDI, IDSAI, PERDIC I, PDS PATKLIN, PPNI - 2005
  34. 34. Summary Dengue disease burden is significantly increased across continents Case management is relatively simple and inexpensive  could saves the lives of patients Revised guidelines ( 2009 and 2011) are available Proposed National guideline ? Changes might be slowly, difficult but inevitable
  35. 35. Signs of Significant Dehydration- Tachychardia- Increased capillary refill time (>2 second)- Cool, mottled or pale skin- Diminished peripheral pulses- Changes in mental status- Oliguria- Sudden rise in haematocrit or continously elevated haematocrit despite administration of fluids- Narrowing of pulse pressure (< 20 mmHg)- Hypotension (a late finding representing uncorrected shock) back
  36. 36. Warning signs (2011) No clinical improvement or worsening of the situation just before or during the Transition to afebrile phase or as the disease progresses. Persistent vomiting, not drinking. Severe abdominal pain. Lethargy and/or restlessness, sudden behavioural changes. Bleeding: Epistaxis, black stool, haematemesis, excessive menstrual bleeding, darkcoloured urine (haemoglobinuria) or haematuria. Giddiness. Pale, cold and clammy hands and feet. Less/no urine output for 4–6 hours. back
  37. 37. Admission criteria 2009 – p 47 backWarning signs Any of the warning signs (Textbox C)Signs & symptoms Dehydrated patient, unable to tolerate oral fluidsrelated to hypotension Giddiness or postural hypotension(possible plasma Profuse perspiration, fainting, prostration during deferescenceleakage) Hypotension or cold extremitiesBleeding Spontaneous bleeding, independent of the platelet countOrgan impairment Renal, hepatic neurological or cardiac - enlarged, tender lier, although not yet in shock - Chest pain or respiratory distress, cyanosisFindings through Rising hematocritfurther investigation Pleural effusion, ascites or asymptomatic gall bladder thickeningCo-existing conditions Pregnancy Co-morbid conditions, such as diabetes mellitus, hypertension peptic ulcer, hamolitic anemias and others Overweight or obese (rapid venous access difficult in emergency) Infancy or old ageSocial circumstances Living alone, living far from healt facility, without reliable means of transport
  38. 38. High-risk patients (2011) infants and the elderly, obesity, pregnant women, peptic ulcer disease, women who have menstruation or abnormal vaginal bleeding, haemolytic diseases such as glucose-6-phosphatase dehydrogenase (G- 6PD) deficiency, thalassemia and other haemoglobinopathies, congenital heart disease, chronic diseases such as diabetes mellitus, hypertension, asthma, ischaemic heart disease, chronic renal failure, liver cirrhosis, patients on steroid or NSAID treatment, and others back
  39. 39. Rate of Infusion in DSS (2011) back
  40. 40. 1997 back